Abstract
A group of structurally related thiazoloazepines displaying high affinity for histamine receptors of the H3 subtype, with pKi values in the range of 7.5 – 9.5, are disclosed in the latest of a series of such applications from Glaxo. These compounds have potential utility in the treatment of CNS disorders, in particular for the improvement of cognitive deficits and alleviation of some symptoms of Alzheimer’s disease, when administered either alone or in combination with other psychotherapeutic agents, for example, muscarinic M1 agonists or acetylcholinesterase inhibitors.
Keywords::
Patent details
Title Fused thiazole derivatives having affinity for the histamine H3 receptor
Assignee Bailey N, Pickering PL,Wilson DM
Inventors Glaxo Group Ltd
Priority date 14/03/05
Filing date 10/03/06
Publication date 21/09/06
Publication no. WO2006097691